Infliximab has an important role in the treatment of psoriatic arthritis (PsA) and is recommended by clinical guidelines. [1][2][3][4] In 2013 and 2016, respectively, the intravenously (IV) administered infliximab biosimilar CT-P13 IV received regulatory approval from the European Medicines Agency (EMA) and US Food and Drug Administration for the same indications as reference infliximab. 5-9 A subcutaneous (SC) formulation of CT-P13 (CT-P13 SC)-the first and only SC infliximab formulation-has since been developed, which may benefit patients and healthcare systems. 10 Clinical trials in patients with rheumatoid arthritis 11 and inflammatory bowel disease 12 demonstrated the non-inferiority of CT-P13 SC to CT-P13 IV in terms of efficacy and pharmacokinetics, respectively, alongside comparable safety profiles. In July 2020, the European Commission granted an extension of the marketing authorization for CT-P13 SC to indications including PsA 13 ; this was based on extrapolation rather than clinical trial
The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.